Contents
On this page
- Scope and limits of this article
- The scale of disease burden addressed by these tools
- Measurement as technology: the development of patient-reported outcome measures (PROMs)
- Development without adoption as a documented limitation
- The geographic origin of instruments as a limitation
- Capabilities and limits of large-scale measurement
- Reporting technology-derived outcomes
- Areas of limited evidence and the claims this article does not make
- Describing a health technology without overclaiming
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · Limits of health technology
Impacts and Limitations of Technology in Healthcare: What the Evidence Shows
This article is deliberately narrower than its title suggests. Peer-reviewed evidence for broad claims about the impact of technology on healthcare could not be sourced, so the article addresses the area that is documented: measurement technology. Churruca and colleagues found that, of 315 patient-reported outcome measures, 85.7% were taken up in further research but only 16.2% had any reported clinical or policy use.
Articles on technology in healthcare commonly open with a broad claim of transformation and cite no sources. A search for the evidence behind such claims did not locate it, not because the evidence is hidden, but because the question is too broad to have been studied as posed. What has been studied is narrower and more useful to researchers writing about a health technology: how measurement instruments are developed, how far they are adopted in practice, who develops them, and the scale of the disease burden they are intended to address. This article covers that evidence and states where it ends.
Learning objectives
- Why “the impact of technology on healthcare” is not an answerable research question as usually posed
- The documented adoption gap in measurement technology: 85.7% taken up in research against 16.2% with reported clinical or policy use
- Where instruments are built — 46.8% in the United States, 25.8% in the United Kingdom — and why that is a limitation of the technology itself
- The scale of burden these tools are deployed against, from the Global Burden of Disease estimates
- How to report a technology-derived outcome so that readers can evaluate it
- Which claims about health technology should not be made in a manuscript, because no evidence supports them
Common misconceptions
- “Technology has transformed healthcare outcomes.” A claim of that generality cannot be supported or refuted by any study, which is why it typically appears without citations. Narrowed to one technology, one outcome and one population, it becomes answerable.
- “A validated instrument is in use.” Development is not adoption. In Churruca and colleagues’ review, 45 of 315 instruments had no evidence of subsequent use at all, and only 51 had any online report of clinical or policy use.
- “Measurement tools are neutral.” They encode what their developers considered important. Of the 315 instruments reviewed, 147 originated in the United States and 81 in the United Kingdom; 12 came from Australia and 29 from Canada.
- “A population-level reference model provides information about an individual patient.” Normative models describe distributions. An individual’s position in a distribution is not a diagnosis, and reporting it as one is a measurement error rather than a clinical insight.
- “Where the evidence is limited, authors should write around it.” The opposite applies. A paper that states the limits of its evidence is more useful and more citable than one that obscures them, and reviewers recognise the difference.
Scope and limits of this article
The difficulty with the subject should be stated directly. “The impacts and limitations of technology in healthcare” is not a question that research answers, because it is not one question. It combines electronic records, imaging, diagnostics, telemedicine, devices, algorithms, registries and measurement instruments — each with different evidence, different failure modes and different populations — under a single noun. A search for peer-reviewed sources supporting general claims about the effect of technology on healthcare did not identify any. Articles making such claims typically cite nothing, or cite commentary.
Rather than supplement the page with unsupported assertions, this article narrows the subject to a technology for which evidence does exist: measurement. Patient-reported outcome measures are a health technology in the ordinary sense — engineered artefacts that make measurable something that was not previously measurable — and they have been studied as such. The findings about them generalise usefully, because the pattern they show (vigorous development, slow and uneven translation into practice, concentrated origins) appears to be the pattern that most health technologies follow.
For authors of a manuscript or a grant application about a health technology, the practical lesson precedes any of the evidence: the claim should be narrowed until it is answerable. One technology, one outcome, one population, one comparator. A sentence that withstands that narrowing is a sentence that can be defended.
The scale of disease burden addressed by these tools
One element of context merits establishing, because it is well measured and it defines the stakes. The GBD 2021 Nervous System Disorders Collaborators, writing in The Lancet Neurology, estimated that in 2021 disorders affecting the nervous system were the leading grouped cause of disability-adjusted life-years worldwide: 443 million DALYs, with a 95% uncertainty interval of 378 to 521 million, affecting 3.40 billion people — 43.1% of the world’s population 32. The analysis covered 37 conditions across 204 countries and territories.
Two features of that estimate are instructive for authors writing about health technology. The first is the uncertainty interval, which spans roughly 140 million DALYs. This is not a weakness in the estimate; it reflects an accurate statement of what can be known from the available data, and it is the standard to which a technology claim should be held. The second is that a figure of this kind is itself a product of measurement technology — standardised case definitions, modelling infrastructure, and a very large coordinated data pipeline 32. The figure exists because the apparatus required to produce it was built.
The figure does not, however, establish that any particular technology improved any outcome. It establishes the size of the problem, which is a different claim and the one that can be made safely.
Measurement as technology: the development of patient-reported outcome measures (PROMs)
A patient-reported outcome measure is an instrument that turns something subjective — pain, fatigue, function, distress — into a score that can be compared across people and over time. Churruca and colleagues, in Health Expectations, review the landscape of generic and condition-specific measures and the issues that arise from how they are chosen and used 9.
The most substantial engineering effort in this area is PROMIS. Cella and colleagues, in the Journal of Clinical Epidemiology, describe how the Patient-Reported Outcomes Measurement Information System developed and tested its first wave of adult self-reported health outcome item banks over the period 2005 to 2008 20. This illustrates the nature of the work: item banks built, calibrated and tested over several years before any instrument is ready for use. The process is slow, expensive and invisible to the clinicians who later use the output, which partly explains why instrument selection is so often treated as a lookup rather than a decision.
For researchers, the implication is that an instrument carries its construction with it. The population on which it was calibrated, the anchor against which it was calibrated, and its score range are all properties of the tool that constrain what a result means. An instrument validated in one population and applied in another measures something, but not necessarily the construct it was validated to measure — and this is a methods problem, not a discussion-section caveat. Our reporting guidelines page covers what has to be stated.
Development without adoption as a documented limitation
This is the clearest evidence-based limitation of a health technology identified for this article. Of the 315 patient-reported outcome measures Churruca and colleagues examined, 270 — 85.7% — were used in subsequent research 9. However, only 51, or 16.2%, had any online report of clinical or policy use, and 45 instruments had no evidence of subsequent use at all.
These figures warrant careful interpretation. The instruments circulate widely within research, where they generate publications, but rarely reach practice and policy. Moreover, 45 of them were developed and then not used by anyone, including their developers. This constitutes a translation failure, and it is the type of finding that is lost when technology is discussed at the level of transformation narratives 9.
Several plausible explanations may account for it, and the defensible position is that the review documents the gap rather than explaining it 9. Instruments may be developed to answer a research question rather than to fit a clinical workflow. Licensing and cost may obstruct routine use. There may be too many instruments measuring the same construct, so that no single one accumulates the evidence base that would justify adoption. Clinical systems may lack a place to record the data. Use may also be undercounted, since clinical deployment leaves less of an online trace than publication does. All of these explanations are reasonable; none is established by this evidence.
For developers of any health technology, the figure of 16.2% is particularly instructive. Development is the stage that attracts funding; adoption is the stage that determines whether the technology had any effect.
Patient-reported outcome measures: research uptake against reported clinical or policy use, from 315 instruments reviewed (270 used in research; 51 with clinical or policy use). Clinical use may be undercounted, as deployment leaves less online trace than publication. Source: Churruca K, Pomare C, Ellis LA, et al. Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. Health Expectations.
The geographic origin of instruments as a limitation
The same review documents the origins of these tools, and the concentration is substantial. Of the 315 instruments, 147 (46.8%) originated in the United States, 81 (25.8%) in the United Kingdom, 29 (9.2%) in Canada and 12 (3.8%) in Australia 9. Four high-income, predominantly English-speaking countries account for the overwhelming majority 9.
The consequence is straightforward to state but difficult to remedy. An instrument encodes assumptions about what counts as functioning, which activities are relevant to daily life, how distress is expressed, what family and work arrangements look like, and how people describe their bodies. Items developed in one setting and translated into another achieve linguistic equivalence long before cultural equivalence, and a score that is comparable on paper may not be comparable in meaning.
For researchers using one of these instruments outside the setting in which it was developed, this is a methods issue with a specific obligation: to state where the instrument was developed, in which population it was validated, and what cross-cultural validation exists for the study setting. If none exists, this should be stated. Such a limitation has a direction — it makes the scores harder to interpret against published norms — and reviewers generally respond better to a stated limitation than to one they discover.
Country of origin for the 315 patient-reported outcome measures reviewed. Source: Churruca K, Pomare C, Ellis LA, et al. Health Expectations.
Capabilities and limits of large-scale measurement
Measurement technology is at its most impressive when it establishes a reference distribution across a population. Bethlehem and colleagues’ brain charts for the human lifespan, in Nature, are a representative example of the genre: pooled imaging data assembled into normative growth curves spanning the lifespan, built on infrastructure for harmonising measurements made at many sites on different scanners 6.
Work of this kind offers a genuinely new capability. It makes it possible to ask whether a measurement is unusual for a person’s age, which previously could be judged only impressionistically. It is also routinely overinterpreted, and the overinterpretation follows a consistent pattern: a position in a distribution is treated as a clinical finding. A centile is not a diagnosis. It indicates how common a value is, not whether it is pathological, what caused it, or what should be done. Reference models also carry the demographic composition of the data on which they were built, so a centile becomes less informative the further a person sits from the populations contributing the data 6.
When a normative model is used in a manuscript, the obligations are to name the model and version, state the reference population, and avoid converting a percentile into a clinical claim. Our AI in imaging hub covers the parallel case where the technology is algorithmic rather than normative.
Reporting technology-derived outcomes
Much of the weakness in the reporting of health technologies arises at the methods stage, where an instrument is named and nothing further is reported. The remedy is brief and largely mechanical, and it converts a vague outcome into one that a reader can evaluate.
The same patient-reported outcome, described two ways (a constructed specimen)
Names the instrument and stops
Quality of life was assessed using a validated questionnaire at baseline and at six months. Scores were compared between groups. Technology-enabled remote monitoring was associated with improved quality of life.
The instrument is unnamed. “A validated questionnaire” tells a reader nothing about what was measured.
“Validated” for what, in whom? Validation is population-specific; the word alone asserts fitness without evidencing it.
No scoring direction or range. A reader cannot determine whether an increase is favourable or how large a change of 6 points would be.
Missing data unmentioned. Patient-reported outcomes are missing non-randomly, which is typically the first issue a reviewer raises.
Score change equated with patient improvement. “Improved quality of life” is a claim the measurement cannot carry on its own.
Lets a reader judge it
The primary outcome was health-related quality of life measured with the [named instrument, version], a 20-item condition-specific measure developed and validated in a United States outpatient population, scored 0–100 with higher scores indicating better function and a published minimum clinically important difference of 5 points. No cross-cultural validation has been published for our setting, and scores should not be compared against published norms for that reason. Instruments were self-completed at baseline and six months; 11% of six-month questionnaires were missing and were handled by multiple imputation. Mean scores rose by 6.2 points (95% CI 2.1 to 10.3) in the remote monitoring arm against 1.8 points (95% CI −1.6 to 5.2) in usual care. We report a change in measured scores; whether clinical status changed correspondingly was not assessed.
The instrument, version, length, construct and development population are all stated.
Scoring direction, range and the minimum clinically important difference let a reader size the effect.
The absence of cross-cultural validation is declared, with its consequence — a limitation with a direction.
Missing data are quantified and the handling named.
The claim is confined to measured scores, with the gap to clinical status stated rather than elided.
The second version makes a smaller claim and is considerably more robust to criticism. Each addition addresses an objection: what was measured, whether the instrument fits this population, the size of the effect in the instrument’s own units, whether attrition could explain it, and whether a score change justifies a statement about patients. The last of these is the most important when the technology is the measurement itself, because an instrument can become more sensitive without any patient improving.
Areas of limited evidence and the claims this article does not make
What this article does not establish should be stated explicitly, since most writing on the topic implies considerably more.
This article presents no evidence that any health technology improves patient outcomes in general. It presents no evidence on electronic records, telemedicine, wearables, decision support or clinical algorithms, because no peer-reviewed source on their aggregate impact was identified among the sources for this article — a statement about this article’s evidence base, not a claim that such evidence does not exist elsewhere. It offers no explanation for the adoption gap, only the gap itself. Nor does it present evidence on whether the geographic concentration of instrument development has measurable consequences for patients, although the mechanism is sufficiently clear to be stated as a limitation.
One adjacent finding merits reporting because it illustrates where measured comparisons are made. Xiang and colleagues, in Frontiers in Medicine, conducted a systematic review and meta-analysis of case-based learning in Chinese nursing education and found that combining case-based with problem-based learning produced a mean difference of 32.06 (95% CI 23.33 to 40.79) against 16.53 (95% CI 4.85 to 28.21) for case-based learning alone 2. This is a finding about teaching method, not about technology, and it is not presented here as the latter. It demonstrates that a question of this kind becomes measurable once it is specified sufficiently narrowly — a defined intervention, a defined comparator, a defined outcome 2. Yu and colleagues, in Nurse Education in Practice, ran a cluster randomised trial of blended against offline case-centred learning on the same logic 8.
The transferable lesson is methodological. “Does technology help healthcare?” has no answer. “Does this instrument, administered in this population, detect a change that this other instrument misses?” does. In this area, narrowing the question constitutes the principal methodological task.
What we can and cannot say about health technology on the evidence in this article
| Claim | Status here | Source or gap |
|---|---|---|
| Measurement instruments are developed far more often than they are adopted | Supported | 85.7% research use against 16.2% clinical or policy use, across 315 instruments (Churruca et al., Health Expectations) |
| Instrument development is geographically concentrated | Supported | 147 US, 81 UK, 29 Canada, 12 Australia of 315 (Churruca et al.) |
| Building an item bank is a multi-year engineering effort | Supported | PROMIS first wave of adult item banks developed and tested 2005–2008 (Cella et al., Journal of Clinical Epidemiology) |
| The burden these tools address is very large | Supported | 443 million DALYs (95% UI 378–521), 3.40 billion people, 43.1% of the population, across 37 conditions in 204 countries (GBD 2021, The Lancet Neurology) |
| Population reference models can situate an individual measurement | Supported in principle | Brain charts for the human lifespan (Bethlehem et al., Nature). A centile is not a diagnosis |
| Why the adoption gap exists | Not established | The review documents the gap; licensing, workflow fit, instrument proliferation and undercounting are plausible but untested |
| Geographic concentration harms patients | Not established | Mechanism is clear; no evidence here measures the consequence |
| Technology improves healthcare outcomes generally | Not answerable as posed | No peer-reviewed source for a claim at this level surfaced for this article |
| Electronic records, telemedicine, wearables or decision support have a net benefit | Outside this evidence base | Nothing in our sources addresses these; absence here is not evidence against them |
Compiled for this article from the sources named in each row. The status column is our assessment of what these sources support, not a finding published by any of them.
Describing a health technology without overclaiming
Four practices address most of these issues, and none of them is costly.
Name the technology at the level you studied it. Not “digital health” but the specific instrument, device, model or system, with its version. A claim attached to a category cannot be tested; a claim attached to a version can.
Report the provenance. Authors should state where the technology was developed, on which population, against what it was validated, and what evidence exists for the study setting. Where that evidence is absent, this should be stated in the limitations together with its direction — usually that the scores cannot be compared against published norms.
Keep the outcome separate from the technology. “Scores improved” and “patients improved” are different claims, and an instrument that becomes more sensitive can produce the first without the second. This is the distinction most often conflated, and reviewers in this area specifically look for it.
State the uncertainty in the same sentence as the estimate. The GBD figures cited above are a useful model: a point estimate with an interval wide enough to represent the uncertainty accurately. Where the evidence base is limited, as for much of this article, stating so is more useful than writing around it. Our page on common medical writing mistakes covers the claim-to-design mismatch in more detail, and biostatistics support is appropriate where the measurement model itself is in question.
Key points
Key points
No answerable research question corresponds to “the impact of technology on healthcare”, and pages that claim to answer it generally cite no sources. What is documented, at least for measurement technology, is a translation failure: of 315 patient-reported outcome measures, 85.7% were taken up in further research but only 16.2% had any reported clinical or policy use, and 45 had no evidence of subsequent use. Instrument development is also highly concentrated, with 147 of the 315 originating in the United States and 81 in the United Kingdom, which constrains the meaning of a score when an instrument is used elsewhere. Authors writing about a health technology should narrow the claim to one technology, one outcome, one population and one comparator, report the instrument’s provenance and validation, distinguish “scores improved” from “patients improved”, and state uncertainty where it exists. Much of the subject of this article lacks an evidence base, and the article states this rather than filling the gap.
Application to your study
Application to your study
- The claim should be narrowed until it is testable. It should concern one named technology with its version, one outcome, one population and one comparator. A claim attached to a category cannot be assessed.
- The specific instrument, rather than its genre, should be named. “A validated questionnaire” is not a methods statement. The instrument, version, item count, construct and scoring direction should be reported.
- The setting in which the instrument was developed and validated should be stated. If no cross-cultural validation exists for the study setting, this should be stated together with its consequence, namely that scores are not comparable with published norms.
- The minimum clinically important difference should be reported where one has been published. Without it, readers cannot judge whether the effect size is meaningful.
- Missing questionnaires should be quantified and their handling described. Patient-reported outcome data are missing non-randomly, and reviewers will raise the issue if it is not addressed.
- Score change and clinical change should be kept distinct. Authors should write “measured scores rose” unless clinical status was also assessed; the two are routinely conflated.
- A percentile from a reference model should be treated as a position, not a diagnosis. The model, its version and its reference population should be named.
- Uncertainty should be reported in the same sentence as the estimate. A point estimate with an appropriate interval is more persuasive than an unqualified figure.
- Where the evidence base is limited, this should be stated in the paper. A stated gap is more useful and more citable than a padded paragraph, and reviewers recognise the difference.
Frequently asked questions
Stated at that level, the question has no evidence-based answer, and acknowledging this is preferable to supplying a list that merely sounds authoritative. What is documented, for measurement technology, is a translation failure: Churruca and colleagues, in Health Expectations, found that of 315 patient-reported outcome measures, 270 (85.7%) were used in subsequent research but only 51 (16.2%) had any online report of clinical or policy use, and 45 had no evidence of subsequent use at all. A second documented limitation is concentration of origin — 147 of those instruments came from the United States and 81 from the United Kingdom — which constrains what a score means when the instrument is used elsewhere.
Because the question bundles together things with different evidence, different failure modes and different populations: imaging, records, diagnostics, devices, telemedicine, algorithms, registries and measurement instruments. There is no study design that could evaluate the bundle, which is why articles making claims at this level cite commentary or nothing at all. The question becomes answerable when it is narrowed to a specified intervention, comparator, outcome and population. Xiang and colleagues’ meta-analysis in Frontiers in Medicine illustrates the point from an adjacent field — a tightly specified comparison of teaching methods yielded a mean difference of 32.06 (95% CI 23.33 to 40.79) for combined case-based and problem-based learning against 16.53 (95% CI 4.85 to 28.21) for case-based learning alone — which is a finding about teaching, not technology, but shows what specification buys.
It is an instrument that converts something subjective — pain, fatigue, function, distress — into a score comparable across people and over time. It counts as technology in the ordinary sense: an engineered artefact that makes something measurable which was not measurable before. The engineering effort is substantial and mostly invisible to users. Cella and colleagues, in the Journal of Clinical Epidemiology, describe how PROMIS developed and tested its first wave of adult self-reported health outcome item banks over the period 2005 to 2008. Because the construction is invisible, instrument selection is often treated as a lookup rather than as a methodological decision, which is the source of many subsequent problems.
Because an instrument encodes assumptions about what counts as functioning, which daily activities are relevant, how distress is expressed and how people describe their bodies, and those assumptions travel with it. Of the 315 instruments Churruca and colleagues reviewed, 147 (46.8%) originated in the United States, 81 (25.8%) in the United Kingdom, 29 (9.2%) in Canada and 12 (3.8%) in Australia — four high-income, largely English-speaking countries. Translation achieves linguistic equivalence long before cultural equivalence, so a score that appears comparable may not be comparable in meaning. When an instrument is used outside its development setting, authors should state this, report what cross-cultural validation exists and, if none exists, acknowledge it in the limitations.
No, and the gap is larger than many researchers expect. In the same review, 85.7% of instruments were used in subsequent research but only 16.2% had any online report of clinical or policy use, and 45 had no evidence of subsequent use at all. Several explanations are plausible — instruments built to answer a research question rather than to fit a workflow, licensing and cost barriers, too many instruments measuring the same construct so that none accumulates a case for adoption, clinical systems lacking a place to record the data, and genuine undercounting because clinical deployment leaves less online trace than publication. The review documents the gap without establishing its cause, and it is more accurate to report it in those terms.
They can indicate an individual’s position in a distribution, and nothing more. Work such as Bethlehem and colleagues’ brain charts for the human lifespan, in Nature, makes it possible to ask whether a measurement is unusual for a person’s age — a genuinely new and useful capability. However, a centile is not a diagnosis: it reports how common a value is, not whether it is pathological, what caused it, or what should be done. Reference models also carry the demographic composition of the data from which they were built, so a centile becomes progressively less informative the further an individual sits from the contributing populations. In a manuscript, authors should name the model and version, state the reference population, and refrain from converting a percentile into a clinical claim.
Four practices address most of the problem. The technology should be named at the level at which it was studied, with its version, rather than as a category. Its provenance should be reported — where it was developed, on which population, against what it was validated, and what evidence exists for the study setting. “Scores improved” should be kept separate from “patients improved”, because an instrument that becomes more sensitive can produce the first without the second, and reviewers in this area specifically look for this distinction. Finally, uncertainty should be stated in the same sentence as the estimate: the GBD 2021 nervous system figures are a good model, reporting 443 million DALYs with a 95% uncertainty interval of 378 to 521 million rather than a single point estimate.
On the contrary, it is one of the few practices that reliably improves how a paper is received. A stated gap shows a reviewer that the authors understand the limits of their own evidence; a padded paragraph suggests that they do not, or that they hope the gap will pass unnoticed. This article follows that principle: peer-reviewed evidence for general claims about the impact of technology on healthcare could not be sourced, and the article states this rather than supplying confident prose. In a manuscript, the equivalent is a limitations section in which each weakness is accompanied by the direction in which it would bias the estimate, and a conclusion scaled to what the design can support rather than to the result the authors hoped to find.
References
- International Committee of Medical Journal Editors (ICMJE). Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 2026. read 9 October 2026. icmje.org
- Xiang Y, Liu D, Liu L, Liu IC, Wu L, Fan H. Impact of case-based learning on critical thinking dispositions in Chinese nursing education: a systematic review and meta-analysis. Frontiers in Medicine. 2025;12:1452051. doi:10.3389/fmed.2025.1452051 read 9 October 2026. doi.org/10.3389/fmed.2025.1452051
- Bloothooft M, Pennings HJM, van der Heyden MAG. The Utrecht University Honours Program review project: example based scientific publishing training aimed at bachelor medical students. BMC Medical Education. 2024;24(1):1-12. doi:10.1186/s12909-024-05098-7 read 9 October 2026. doi.org/10.1186/s12909-024-05098-7
- Maia D, Andrade R, Afonso J, Costa P, Valente C, Espregueira-Mendes J. Academic performance and perceptions of undergraduate medical students in case-based learning compared to other teaching strategies: a systematic review with meta-analysis. Education Sciences. 2023;13(3):238. doi:10.3390/educsci13030238 read 9 October 2026. doi.org/10.3390/educsci13030238
- Showstark M, et al. Results and lessons learned from a virtual multi-institutional problem-based interprofessional learning approach: the VIPE program. Journal of Interprofessional Care. 2023;37:164-167. read 9 October 2026. frontiersin.org
- Bethlehem RAI, Seidlitz J, White SR, et al. Brain charts for the human lifespan. Nature. 2022;604(7906). doi:10.1038/s41586-022-04554-y read 9 October 2026. doi.org/10.1038/s41586-022-04554-y
- Wong FMF, Kan CWY. Online problem-based learning intervention on self-directed learning and problem-solving through group work: a waitlist controlled trial. International Journal of Environmental Research and Public Health. 2022;19:720. read 9 October 2026. frontiersin.org
- Yu Z, et al. Effects of blended versus offline case-centred learning on the academic performance and critical thinking ability of undergraduate nursing students: a cluster randomised controlled trial. Nurse Education Practice. 2021;53:103080. read 9 October 2026. frontiersin.org
- Churruca K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED, Leahy CJ, Braithwaite J. Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. Health Expectations. 2021;24(4):1015-1024. doi:10.1111/hex.13254 read 9 October 2026. doi.org/10.1111/hex.13254
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:n71. doi:10.1136/bmj.n71 read 9 October 2026. doi.org/10.1136/bmj.n71
- Jawaid SA, Jawaid M. Common reasons for not accepting manuscripts for further processing after editor's triage and initial screening. Pakistan Journal of Medical Sciences. 2019;35(1):1-3. doi:10.12669/pjms.35.1.28 read 9 October 2026. doi.org/10.12669/pjms.35.1.28
- Pasarica M, Bailey M, Cendan JC. Increasing students' publication productivity: could launching a university scientific journal be a catalyst? Cureus. 2019;11(1):e3953. doi:10.7759/cureus.3953 read 9 October 2026. doi.org/10.7759/cureus.3953
- Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. read 9 October 2026. frontiersin.org
- Fujita MSL, Agustin-Lacruz MdC, Terra AL. Journals' guidelines about title, abstract and keywords: an overview of Information Science and Communication Science areas. European Science Editing. 2018;44(4):76-79. read 9 October 2026. europeanscienceediting.org.uk
- Bannas P, Reeder SB. How to write an original radiological research manuscript. European Radiology. 2017;27(11):4455-4460. doi:10.1007/s00330-017-4879-8 read 9 October 2026. doi.org/10.1007/s00330-017-4879-8
- Wager E, Woolley K, Adshead V, Cairns A, Fullam J, Gonzalez J, Grant T, Tortell S. Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey. BMJ Open. 2014;4(4):e004780. doi:10.1136/bmjopen-2013-004780 read 9 October 2026. doi.org/10.1136/bmjopen-2013-004780
- von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement: guidelines for reporting observational studies. International Journal of Surgery. 2014. doi:10.1016/j.ijsu.2014.07.013 read 9 October 2026. doi.org/10.1016/j.ijsu.2014.07.013
- Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology. 2011;64(4):383-394. read 9 October 2026. link.springer.com
- Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11(1). doi:10.1186/1745-6215-11-32 read 9 October 2026. doi.org/10.1186/1745-6215-11-32
- Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. Journal of Clinical Epidemiology. 2010;63(11):1179-1194. doi:10.1016/j.jclinepi.2010.04.011 read 9 October 2026. doi.org/10.1016/j.jclinepi.2010.04.011
- Kuper A, Reeves S, Levinson W. An introduction to reading and appraising qualitative research. BMJ. 2008;337:a288. read 9 October 2026. link.springer.com
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. read 9 October 2026. link.springer.com
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD read 9 October 2026. doi.org/10.1136/bmj.39335.541782.AD
- Kliewer MA. Writing it up: a step-by-step guide to publication for beginning investigators. American Journal of Roentgenology. 2005;185:591-596. read 9 October 2026. tech.snmjournals.org
- Sollaci LB, Pereira MG. The Introduction, Methods, Results, and Discussion (IMRAD) structure: a fifty-year survey. Journal of the Medical Library Association. 2004;92(3):364-371. read 9 October 2026. genreacrossborders.uwaterloo.ca
- International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Annals of Internal Medicine. 1997;126(1):36-47. read 9 October 2026. stat.cmu.edu
- Vickery B. The Royal Society Scientific Conference of 1948. Journal of Documentation. 1992;54(3):281-283. read 9 October 2026. stat.cmu.edu
- Atkinson D. The evolution of medical research writing from 1735 to 1985: the case of the Edinburgh Medical Journal. Applied Linguistics. 1992;13(4):337-374. read 9 October 2026. stat.cmu.edu
- Huth EJ. Structured abstracts for papers reporting clinical trials. Annals of Internal Medicine. 1987;106(4):626-627. read 9 October 2026. stat.cmu.edu
- Meadows AJ. The scientific paper as an archaeological artifact. Journal of Information Science. 1985;11(1):27-30. read 9 October 2026. stat.cmu.edu
- Bazerman C. Modern evolution of the experimental report in physics: spectroscopic articles in Physical Review, 1893-1980. Social Studies of Science. 1984;14:163-196. read 9 October 2026. stat.cmu.edu
- GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology. 23(4):344-381. read 9 October 2026. ro.uow.edu.au
- Radiology (Radiological Society of North America). Radiology scientific style guide and author instructions: scientific editing. Radiology. read 9 October 2026. pubs.rsna.org
- Fernandez E, Garcia AM, Seres E, Bosch F. Students' satisfaction and perceived impact on knowledge, attitudes and skills after a 2-day course in scientific writing: a prospective longitudinal study in Spain. BMJ Open. 8(1):e018657. read 9 October 2026. bmjopen.bmj.com
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Impacts and Limitations of Technology in Healthcare: What the Evidence Shows. Pubrica. https://pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/
Pubrica Academy. “Impacts and Limitations of Technology in Healthcare: What the Evidence Shows.” Pubrica, 9 Oct. 2026, pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/.
Pubrica Academy (2026) Impacts and Limitations of Technology in Healthcare: What the Evidence Shows. Pubrica. Available at: https://pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/ (Accessed: 15 October 2026).
Pubrica Academy. “Impacts and Limitations of Technology in Healthcare: What the Evidence Shows.” Pubrica. October 9, 2026. https://pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/
Pubrica Academy, ‘Impacts and Limitations of Technology in Healthcare: What the Evidence Shows’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/> accessed 15 October 2026.
Pubrica Academy. Impacts and Limitations of Technology in Healthcare: What the Evidence Shows. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/
Pubrica Academy, “Impacts and Limitations of Technology in Healthcare: What the Evidence Shows,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/
@misc{what_are_the_impacts_and_limitations_o_2026,
author = {{Pubrica Academy}},
title = {Impacts and Limitations of Technology in Healthcare: What the Evidence Shows},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/latest-topics/what-are-the-impacts-and-limitations-of-technology-in-healthcare-industries/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Reporting checklist for a technology-derived outcome
This checklist applies wherever the outcome is derived from an instrument, device, model or system rather than from direct observation. Each line addresses an item that a reviewer would otherwise query. It should be completed at the methods stage, not at submission.
HEALTH TECHNOLOGY REPORTING CHECKLIST
1. SPECIFY THE CLAIM
Technology (name AND version): ______________________________
Outcome measured: ___________________________________________
Population: _________________________________________________
Comparator: _________________________________________________
[ ] The claim names a specific technology, not a category
("digital health", "AI", "remote monitoring" are categories)
2. THE INSTRUMENT / MODEL ITSELF
Name and version: ___________________________________________
Number of items / inputs: ______
Construct it measures: ______________________________________
Generic or condition-specific: ______________________________
Score range: ______ to ______
Direction (higher = better/worse): __________________________
Published minimum clinically important difference: ______
3. PROVENANCE AND VALIDATION
Developed in (country, setting, year): ______________________
Validated in which population: ______________________________
Validated against which anchor or reference standard: ________
Cross-cultural validation for MY setting: [ ] yes [ ] none
If none, limitation stated as:
"Scores cannot be compared against published norms for this
instrument because no cross-cultural validation exists for
this population."
Licensing / permission obtained: [ ] yes [ ] not required
4. ADMINISTRATION
Mode (self-complete / interview / device-captured): __________
Who administered it, and were they blinded: _________________
Time points: _________________________________________________
Setting of completion: ______________________________________
5. MISSING DATA (patient-reported outcomes go missing NON-randomly)
Missing at each time point: ______ %
Handling method: ____________________________________________
[ ] Sensitivity analysis under a different missingness assumption
6. REFERENCE MODELS, IF USED
Model name and version: _____________________________________
Reference population and its composition: ___________________
[ ] No percentile is reported as a diagnosis
[ ] Distance of my population from the reference population noted
7. THE CLAIM BOUNDARY
[ ] Results state "measured scores" where only scores were measured
[ ] Any statement about patient status is separately evidenced
[ ] Estimate reported WITH its interval, in the same sentence
[ ] Limitations each carry a DIRECTION of likely bias
[ ] Conclusion scaled to the design, not to the hope
8. HONEST GAPS
What my evidence does NOT establish:
__________________________________________________________
__________________________________________________________
[ ] This appears in the paper, not only in my notes Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica works on manuscripts in which the outcome derives from an instrument, device or model rather than direct observation, checking that the instrument, its version, its development population and its validation status are reported, that missing questionnaire data are quantified and handled, and that the paper does not move from measured scores to claims of patient improvement. Where the evidence for a claim does not exist, Pubrica advises the authors before the paper is built around it.